Delcath (DCTH): Debts to Book Capitalization

Graphic logo of Delcath Systems Inc (DCTH)

The market capitalization trend for Delcath Systems, Inc. (DCTH) reflects dynamics based on the development of blood filtration systems for localized liver treatment, which reduces overall therapy toxicity. Production stability is ensured through the creation of component reserves, eliminating assembly downtime. The current metric stands at 0.02, while the business relies on the closed CHEMOSAT ecosystem, which strictly binds clinics to brand regulations.

Delcath Systems, Inc. (DCTH) - Debts to Book Value from 07/04/2022 to 10/27/2026
Core merchandise of Delcath Systems Inc

This ratio determines the company's degree of dependence on borrowed funds by comparing total liabilities to equity to assess default risks and the efficiency of financial leverage. By analyzing the dynamic trend of financial leverage on the balance sheet, an investor can see how Delcath Systems, Inc. (DCTH) balances its debt load against the resources required for the commercialization of liver cancer treatment systems during the regulatory approval period.

Who Delcath Systems, Inc. competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Y-mAbs Therapeutics Inc (YMAB)|Aura Bio - Debts to Book Capitalization|CADL - Debt to Book Value|Accuray Incorporated - Debt to Book Value|SLS: Debts to Book Capitalization|Debt to Book Capitalization Ratio Actuate Therapeutics ACTU|Citius Oncology Inc. (CTOR) - Debt to Net Assets Ratio|Debts to Book Capitalization HURA (TuHURA Biosciences Inc.)|Debts to Book Value Protara Tx|Debts to Book Capitalization Fate Therapeutics, Inc. FATE|Debt to Book Value Ratio aadibio.com (WHWK)|TCRX: Debts to Book Capitalization|Champions Oncology Inc - Debts to Book Value|XBIT - Debt to Book Capitalization Ratio|CVM - Debt to Book Capitalization Ratio|OSTX (OS Therapies Incorporated) - Debts to Book Capitalization|radiopharmtheranostics.com (RADX) - Debt to Book Value|ARTV (Artiva Biotherapeutics Inc.) - Debts to Book Capitalization|Debts to Book Capitalization Adlai Nortye Limited (ANL)|Debt to Book Value Veru Pharma|Debt to Book Capital Tempest Therapeutics Corp (TPST)|Debts to Book Capitalization Xilio Therapeutics|RENB - Debt to Net Assets Ratio|Debt to Book Value Mural Bio (MURA)|KAPA: Debt to Net Assets Ratio|onkuretherapeutics.com - Debt to Book Capitalization Ratio|Debts to Net Assets CytoMed Therapeutics Limited|Debt to Book Value CRIS (Curis Inc.)|Debts to Book Value APLM|THAR (Tharimmune) - Debt to Book Capitalization Ratio|Debts to Net Assets advanbiomed.com ADVB|Debt to Book Value Genprex, Inc (GNPX)|Debt to Book Capital Calidi Biotherapeutics Inc. CLDI|SBFM (Sunshine Biopharma, Inc.) - Debts to Book Capitalization|XBIO: Debts to Book Value|SLRX (Salarius Pharmaceuticals, Inc.) - Debt to Book Capitalization Ratio|PPBT (Purple Biotech Ltd) - Debt to Book Value|AONC: Debt to Book Capitalization Ratio|Debts to Net Assets BeiGene Ltd (BGNE)|Checkpoint Therapeutics (CKPT) - Debt to Book Value|Debt to Net Assets Ratio elevationoncology.com (ELEV)|Debts to Book Capitalization ICAD|Ikena Oncology Inc. - Debts to Net Assets|Notable Labs Inc. (NTBL) - Debt to Book Capitalization Ratio|VIRX - Debt to Book Value Ratio|MOR (MorphoSys AG) - Debts to Book Capitalization|Debt to Book Value nayabiosciences.com|AAPGV: Debt to Book Value